Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer
KRAS mutations, particularly KRAS G12C, pose significant therapeutic challenges in non-small cell lung cancer (NSCLC) due to limited inhibitor efficacy and rapid resistance. Drug repurposing offers a time and cost-effective strategy to identify alternative therapeutic options targeting KRAS-driven signalling. A structu...